Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CEO Matthew Gline sold 289,774 shares of the stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $29.16, for a total transaction of $8,449,809.84. Following the completion of the transaction, the chief executive officer directly owned 16,736,116 shares in the company, valued at $488,025,142.56. The trade was a 1.70% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Roivant Sciences Stock Performance
NASDAQ ROIV opened at $29.08 on Tuesday. Roivant Sciences Ltd. has a 52-week low of $10.01 and a 52-week high of $30.33. The company has a market capitalization of $20.81 billion, a P/E ratio of -24.85 and a beta of 1.20. The company has a fifty day moving average of $28.10 and a 200-day moving average of $23.33.
Analysts Set New Price Targets
ROIV has been the subject of several research analyst reports. TD Cowen reaffirmed a "buy" rating on shares of Roivant Sciences in a research note on Wednesday, March 4th. HC Wainwright increased their price objective on Roivant Sciences from $33.00 to $34.00 and gave the company a "buy" rating in a research report on Wednesday, March 4th. Sanford C. Bernstein started coverage on Roivant Sciences in a report on Friday, March 20th. They set an "outperform" rating and a $35.00 price objective on the stock. Guggenheim boosted their target price on Roivant Sciences from $28.00 to $30.00 and gave the stock a "buy" rating in a research report on Monday, February 9th. Finally, Jefferies Financial Group reaffirmed a "buy" rating on shares of Roivant Sciences in a research note on Tuesday, March 3rd. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $30.55.
Check Out Our Latest Research Report on ROIV
Institutional Trading of Roivant Sciences
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. boosted its holdings in Roivant Sciences by 15.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company's stock valued at $24,553,000 after acquiring an additional 324,764 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Roivant Sciences by 1.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company's stock valued at $24,678,000 after purchasing an additional 34,341 shares during the period. American Century Companies Inc. raised its holdings in Roivant Sciences by 1.9% in the 2nd quarter. American Century Companies Inc. now owns 89,625 shares of the company's stock worth $1,010,000 after purchasing an additional 1,689 shares in the last quarter. Russell Investments Group Ltd. lifted its position in shares of Roivant Sciences by 149.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 11,467 shares of the company's stock worth $129,000 after purchasing an additional 6,879 shares during the period. Finally, M&T Bank Corp lifted its position in shares of Roivant Sciences by 10.2% in the 2nd quarter. M&T Bank Corp now owns 12,802 shares of the company's stock worth $144,000 after purchasing an additional 1,181 shares during the period. Hedge funds and other institutional investors own 64.76% of the company's stock.
Roivant Sciences Company Profile
(
Get Free Report)
Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.
The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
